Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Chaves, LL (Author) Other; Patriota, Y (Author) Other; Soares Sobrinho, JL (Author) Other; Vieira, ACC (Author) Other; Costa Lima, SAC (Author) Other; Salette Reis (Author) FFUP

Journal

Title: Pharmaceutics

Vol. 12

Pages: 1-19

ISSN: 1999-4923

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00T-66C

DOI: 10.3390/pharmaceutics12121202

Abstract (EN): Leprosy disease remains an important public health issue as it is still endemic in several countries. Mycobacterium leprae, the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 19